TSVT (2seventy Bio) Long-Term Debt

Corporate emblem and logo of 2seventy bio, Inc (TSVT)

The price history of 2seventy bio, Inc. (TSVT) shares on the GURU.Markets platform, where the indicator stands at 0.24, correlates with the availability of insurance coverage and the quality of drug distribution. The business relies on its own vector creation infrastructure and Abecma patents, limiting customer churn to other providers. Additionally, 2seventy bio, Inc. (TSVT) is implementing automated bioreactors for culture scaling to eliminate human error in the cultivation of modified cells.

TSVT (2seventy Bio) Company Long-Term Debt history from 07/04/2022 to 05/24/2025

Financial and market metric breakdowns for 2seventy Bio (TSVT)

- price and consensus price forecast:
Stock Quotes 2seventybio.com|TSVT - Price Target Chart
- market capitalization data:
Market Value 2seventy bio|TSVT - Total Company Value
- book capitalization data:
Net Assets per Single Share 2seventy bio|TSVT - Company Book Value|Market-to-Book Ratio 2seventybio.com|TSVT - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio 2seventy bio, Inc.|TSVT - Long-Term Debt to Equity Ratio|Current Liabilities to Capital 2seventy bio, Inc|TSVT - Company Total Debt|Debt to Net Assets Ratio 2seventy bio|TSVT - Company Long-Term Debts|Company Current Liabilities 2seventy bio
Comprehensive company analysis:TSVT (2seventybio.com)
Mass-produced product of 2seventy bio

2seventy bio, Inc. (TSVT) is effectively developing cell therapy within a protected U.S. clinical environment. This metric aggregates all obligations with maturities exceeding twelve months, reflecting the long-term credit load. Investors utilize this metric to assess capital resilience against rising interest rates. A neutral geopolitical backdrop minimizes external risks regarding loan servicing. The dynamics of the company's long-term debt levels determine the business's expansion potential.

Competitor analysis for 2seventy bio, Inc.

legendbiotech.com - Company Long-Term Liabilities|SANA (Sana Biotechnology, Inc.) - Company Long-Term Debt|AUTL: Long-Term Debt|Allogene Therapeutics Inc (ALLO) - Company Long-Term Debt|RNAC (Selecta Biosciences Inc.) - Company Long-Term Debt|Company Long-Term Debt CLLS (Cellectis SA)|Long-Term Debt cariboubio.com|TIL: Company Long-Term Debts|Long-Term Indebtedness genenta.com GNTA|IPSC: Company Long-Term Liabilities|JSPR - Long-Term Debt|Company Long-Term Liabilities Senti Biosciences Inc (SNTI)|ADAP - Company Long-Term Loans and Borrowings|CERO (cero.bio) - Company Long-Term Debts|Alaunos Therapeutics, Inc. (TCRT) - Company Long-Term Liabilities|Company Long-Term Debts ACHL (Achilles Therapeutics PLC)|Long-Term Debt CRGX|Company Long-Term Debt Poseida Therapeutics (PSTX)|Company Long-Term Debt GRCL (gracellbio.com)